Literature DB >> 12952290

Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.

David B Paul1, Susana B Read, Nisha V Kulprathipanja, German G Gomez, B K Kleinschmidt-DeMasters, Patric M Schiltz, Carol A Kruse.   

Abstract

In earlier studies, we demonstrated that intratumoral infusions of alloreactive cytotoxic T lymphocytes (aCTL), sensitized to the major histocompatibility complex (MHC) antigens of the host, effectively retarded the intracranial growth of Fischer 9L gliosarcoma. We further demonstrated that continuous in vitro exposure to gamma-interferon (gammaIFN) upregulates MHC on 9L gliosarcoma cells and that they were better targets of anti-Fischer aCTL. We hypothesized that the efficacy of cellular therapy with aCTL could be further improved by in situ transduction of the tumor with retroviral vectors coding for gammaIFN, which would generate continuous secretion of the cytokine and maintain upregulated MHC expression by the tumor cells. 9L gliosarcoma and Herpes simplex virus thymidine kinase (tk) transductants of those cells were transduced with a retrovirus carrying the murine gammaIFN gene. By limiting dilution, clones of these cells, designated 9Lgamma 7, 9Lgamma tk8, and 9Lgamma tk10, which produced similar levels of gammaIFN (383-411 ng gammaIFN/10(6) cells/24 h) were isolated. The production of gammaIFN by one clone, 9Lgamma 7, was stable when monitored over 6 weeks in vitro. The clones also demonstrated upregulated MHC class I expression, and the tk-transduced clones maintained their sensitivity to ganciclovir. Compared to the wildtype cells, 9Lgamma 7 had approximate 6- and 1.5-fold increases in the relative antigen densities of MHC I and II, respectively. Addition of exogenous gammaIFN to 9Lgamma 7 cultures did not significantly increase the MHC expression. In cytotoxicity assays, 9Lgamma 7 cells, or 9Lgamma 7 incubated with exogenous gammaIFN, were better targets of aCTL than the parental 9L cells. The growth rate of 9Lgamma-transduced cells was decreased compared to the wildtype cells both in vitro and in vivo. Proliferation studies with transwell plated 9L, 9Lgamma 7, and 9Lgamma tk10 cells in various combinations revealed that the secreted cytokine itself caused a decrease in proliferation. However, the transduced cells exhibited a much reduced growth rate, which likely was a consequence of redirected metabolic activity of the cells. In vivo growth of the 9L and 9Lgamma 7 tumors in rat brains given identical inoculums similarly demonstrated significantly reduced 9Lgamma 7 tumor volumes at various timepoints, indicative of slower growth of the gammaIFN-producing tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952290     DOI: 10.1007/BF02700024

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  45 in total

1.  Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.

Authors:  L A Lampson; W F Hickey
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

2.  Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-gamma gene.

Authors:  S Miyatake; K Nishihara; H Kikuchi; J Yamashita; Y Namba; M Hanaoka; Y Watanabe
Journal:  J Natl Cancer Inst       Date:  1990-02-07       Impact factor: 13.506

3.  Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.

Authors:  Francis J Burrows; Martin Gore; W Russell Smiley; Martha Y Kanemitsu; Douglas J Jolly; Susana B Read; Thomas Nicholas; Carol A Kruse
Journal:  Cancer Gene Ther       Date:  2002-01       Impact factor: 5.987

4.  Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours.

Authors:  C A Kruse; L T Beck
Journal:  Biotechnol Appl Biochem       Date:  1997-06       Impact factor: 2.431

Review 5.  Brain tumors.

Authors:  E R Laws; K Thapar
Journal:  CA Cancer J Clin       Date:  1993 Sep-Oct       Impact factor: 508.702

6.  Rat ependyma and microglia cells express class II MHC antigens after intravenous infusion of recombinant gamma interferon.

Authors:  B Steiniger; P H van der Meide
Journal:  J Neuroimmunol       Date:  1988-08       Impact factor: 3.478

7.  Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.

Authors:  A Porgador; R Bannerji; Y Watanabe; M Feldman; E Gilboa; L Eisenbach
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

8.  Allogeneic tumor-specific cytotoxic T lymphocytes.

Authors:  J M Redd; A C Lagarde; C A Kruse; D Bellgrau
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro.

Authors:  A Akbasak; E H Oldfield; S C Saris
Journal:  J Neurosurg       Date:  1991-12       Impact factor: 5.115

10.  Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-gamma.

Authors:  M P Sethna; L A Lampson
Journal:  J Neuroimmunol       Date:  1991-11       Impact factor: 3.478

View more
  1 in total

Review 1.  Brain tumor immunotherapy: an immunologist's perspective.

Authors:  Lois A Lampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.